Zacks Investment Research Analysts Increase Earnings Estimates for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXVGet Rating) – Equities researchers at Zacks Investment Research upped their FY2023 earnings estimates for BiondVax Pharmaceuticals in a report released on Monday, May 2nd. Zacks Investment Research analyst D. Bautz now expects that the company will earn ($0.02) per share for the year, up from their previous forecast of ($0.03).

A number of other equities analysts have also issued reports on the company. Aegis assumed coverage on BiondVax Pharmaceuticals in a report on Wednesday, January 26th. They issued a “buy” rating and a $7.00 price objective for the company. StockNews.com assumed coverage on BiondVax Pharmaceuticals in a report on Thursday. They issued a “sell” rating for the company.

NASDAQ:BVXV opened at $1.60 on Thursday. The stock has a 50 day moving average of $1.45 and a 200-day moving average of $1.70. BiondVax Pharmaceuticals has a 52 week low of $1.00 and a 52 week high of $4.19. The company has a quick ratio of 7.64, a current ratio of 7.64 and a debt-to-equity ratio of 2.71.

BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) last posted its earnings results on Monday, March 28th. The company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.18).

A number of hedge funds have recently modified their holdings of the stock. Millennium Management LLC bought a new position in BiondVax Pharmaceuticals during the 2nd quarter valued at $33,000. Citadel Advisors LLC bought a new position in BiondVax Pharmaceuticals during the 3rd quarter valued at $40,000. Envestnet Asset Management Inc. bought a new position in BiondVax Pharmaceuticals during the 4th quarter valued at $118,000. Finally, Morgan Stanley boosted its stake in BiondVax Pharmaceuticals by 24.3% during the 2nd quarter. Morgan Stanley now owns 51,592 shares of the company’s stock valued at $148,000 after purchasing an additional 10,071 shares in the last quarter. 2.96% of the stock is owned by institutional investors and hedge funds.

BiondVax Pharmaceuticals Company Profile (Get Rating)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.

See Also

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.